2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
44
Neoplasm Metastasis
19
Liver Neoplasms
18
Colorectal Neoplasms
15
Cholangiocarcinoma
11
Pancreatic Neoplasms
9
Lung Neoplasms
9
Colonic Neoplasms
9
Breast Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Non-Small-Cell Lung
7
Barrett Esophagus
7
Thyroid Nodule
6
Recurrence
6
Rectal Neoplasms
6
Thyroid Neoplasms
5
Pain
4
Neoplasms
4
Kidney Neoplasms
4
Esophageal Neoplasms
4
Thyroid Cancer, Papillary
3
Prostatic Neoplasms
3
Leiomyoma
3
Biliary Tract Neoplasms
3
Bile Duct Neoplasms
3
Agnosia
3
Thyroid Diseases
2
Hyperaldosteronism
2
Hepatitis B
2
Gallbladder Neoplasms
2
Interventions
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Cisplatin
4
napabucasin
3
Paclitaxel
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
lenvatinib
2
entinostat
2
anlotinib
2
Taxes
2
Sunitinib
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Ocoxin
2
Leucovorin
2
Immunotherapy
2
Fluorouracil
2
Carboplatin
2
vorasidenib
1
sipuleucel-T
1
pralsetinib
1
palbociclib
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
linifanib
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
Radiofrequency Ablation
×
Clear all
NCT02192671
2022-01-18
HR-HCC/PHT
Guangxi Medical University
Phase 3
Unknown
120 enrolled